Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

CPIX Cumberland Pharmaceutical Inc

2,37

0,00 (0,00%)

Vor Marktöffnung

Zuletzt aktualisiert: 13:27:49

Verzögert um 15 Minuten

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Cumberland Pharmaceutical (NASDAQ:CPIX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Cumberland Pharmaceutical Charts.

Cumberland Pharmaceutical (NASDAQ:CPIX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Cumberland Pharmaceutical Charts.

News Cumberland Pharmaceutical Inc

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 31 Dezember 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 31 Dezember 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 9 Dezember 2024 (3 Wochen vor) • Edgar (US Regulatory)

FDA APPROVES ACETADOTE® sNDA
Montag 9 Dezember 2024 (3 Wochen vor) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 5 Dezember 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 5 Dezember 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 5 Dezember 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Freitag 8 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 7 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
Donnerstag 7 November 2024 (2 Monate vor) • PR Newswire (US)

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Mittwoch 6 November 2024 (2 Monate vor) • PR Newswire (US)

Form 8-K - Current report
Mittwoch 6 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Cumberland Pharmaceutical Inc News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen